Clinical Research: Phase 1 - Phase 4

PharmaVoice – Small Pharma Driving Big Pharma Innovation

“Big pharma’s new role in this is to partner and fund the innovation that it so sorely needs to bulk up its dwindling pipelines. This is a cost-effective move for larger drug companies to leverage outside scientific talent to gain access to breakthrough discoveries.

“‘This is a dominant trend in the industry,’ says Nach Davé, VP, development strategy, Premier Research. “Large pharma is deciding that rather than take the risk of developing a single drug over the course of seven to 10 years and spending $7 billion, these companies are taking their chances on innovative, small companies.”

Read more at PharmaVoice: